Human Papillomavirus Vaccination in the Postpartum Period A Systematic Review
Incorporating innovative strategies such as routine postpartum human papillomavirus vaccination would decrease missed cancer-prevention opportunities. OBJECTIVE:To assess whether routine postpartum human papillomavirus (HPV) vaccination is acceptable and feasible and to identify key themes and strat...
Saved in:
Published in | Obstetrics and gynecology (New York. 1953) Vol. 144; no. 6; pp. 782 - 789 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
Lippincott Williams & Wilkins
01.12.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Incorporating innovative strategies such as routine postpartum human papillomavirus vaccination would decrease missed cancer-prevention opportunities.
OBJECTIVE:To assess whether routine postpartum human papillomavirus (HPV) vaccination is acceptable and feasible and to identify key themes and strategies that can be used to increase postpartum HPV vaccination rates.DATA SOURCES:PubMed and ClinicalTrials.gov were queried from inception to July 2024 for postpartum and HPV vaccination. Studies were limited to human subjects and the English language.METHODS OF STUDY SELECTION:Screening was performed for studies of any method that evaluated HPV vaccination in the postpartum period (N=60). Only original research that reported either uptake or acceptability of the HPV vaccine was included. Thirty-nine studies were eliminated after abstract review because they did not meet the inclusion criteria.TABULATION, INTEGRATION, AND RESULTS:Nine studies were categorized according to the primary aim of the study (defining the problem, assessing patient perspectives, or testing interventions to increase vaccination) and demonstrated that postpartum HPV vaccination programs can significantly increase HPV vaccination rates and are feasible and acceptable to patients.CONCLUSION:Incorporating HPV vaccination into standard postpartum care provides an opportunity to reach vulnerable patient populations, reduces cost for patients, and has the ability to prevent HPV-related cancers. |
---|---|
Bibliography: | Corresponding author: Sara E. Brenner, MD, MPH, Department of Gynecology and Obstetrics, Emory University, Atlanta, GA; Sbren22@emory.edu.Financial Disclosure Susan C. Modesitt has served on the Eisai advisory board and received payment from the Onc Live faculty for a National GYN ONC Fellows forum and for a State of the Science talk/meeting. She has served as Editor-in-Chief of the Gynecologic Oncology Reports journal. She received grant support for multi-institutional clinical trials run through the GOG foundation. The other authors did not report any potential conflicts of interest.Presented at the Mid-Atlantic Gynecologic Oncologic Society (MAGOS) meeting, October 26-28, 2023, Charlottesville, Virginia.Each author has confirmed compliance with the journal's requirements for authorship.Peer reviews and author correspondence are available at http://links.lww.com/AOG/D824. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
ISSN: | 0029-7844 1873-233X 1873-233X |
DOI: | 10.1097/AOG.0000000000005718 |